Walleye Capital
BPMC

Walleye Capital’s Blueprint Medicines BPMC Stock Holding History

Walleye Capital’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-500
Closed -$64.1K – 4531
2025
Q2 		$64.1K Buy
500
+300
+150% +$31.2K ﹤0.01% 3956
2025
Q1 		$17.7K Hold
200
– – ﹤0.01% 4017
2024
Q4 		$17.4K Sell
200
-6,600
-97% -$605K ﹤0.01% 4523
2024
Q3 		$629K Sell
6,800
-18,400
-73% -$1.83M ﹤0.01% 3082
2024
Q2 		$2.72M Buy
25,200
+17,500
+227% +$1.75M ﹤0.01% 1827
2024
Q1 		$730K Buy
+7,700
New +$660K ﹤0.01% 2876
2023
Q3 		– Sell
-2,300
Closed -$145K – 4897
2023
Q2 		$145K Sell
2,300
-6,400
-74% -$348K ﹤0.01% 3265
2023
Q1 		$391K Buy
8,700
+5,500
+172% +$248K 0.01% 1906
2022
Q4 		$140K Buy
+3,200
New +$153K ﹤0.01% 2241
2020
Q2 		– Sell
-7,200
Closed -$421K – 631
2020
Q1 		$421K Sell
7,200
-2,500
-26% -$161K 0.09% 263
2019
Q4 		$777K Buy
9,700
+1,100
+13% +$82.4K 0.05% 505
2019
Q3 		$632K Buy
+8,600
New +$743K 0.04% 634

Other funds holding BPMC

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
VanEck Associates
VanEck Associates New York $133B AUM 72.99% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Walleye Capital's BPMC Position: Q3 2025 in Review

Walleye Capital sold out of Blueprint Medicines (BPMC) in Q3 2025, closing a stake of 16,830 shares — an estimated $2.16M sold.

Walleye Capital first reported a position in BPMC in Q2 2020 and held it in 9 quarters. The position peaked at $3.73M in Q1 2025. 5 funds tracked by Wall St. Rank hold BPMC as of Q3 2025.

  • Walleye Capital reported no remaining Blueprint Medicines position as of Q3 2025 after selling out during the quarter.
  • Walleye Capital sold 16,830 Blueprint Medicines shares in Q3 2025, an estimated $2.16M.
  • Walleye Capital first reported a position in Blueprint Medicines in Q2 2020 and held it in 9 quarters.
  • Walleye Capital's Blueprint Medicines position peaked at $3.73M in Q1 2025.
  • 5 funds tracked by Wall St. Rank held Blueprint Medicines as of Q3 2025.

Based on Walleye Capital's 13F filing for Q3 2025, filed 14 Nov 2025.